Dermatology M&A deals were front-loaded in 2024 and significantly quieter in 2025. Across the two years, the sector completed 33 deals totaling $6.4B, with $5.4B in 2024 and $900M in 2025. Cash-only deployment followed the same pattern, totaling $4.4B in 2024 and $800M in 2025, for a combined $5.2B. Deal sizes compressed sharply, with average upfront value declining from $551M to $258M and median upfront value from $513M to $36M, signaling smaller, more structured transactions. Relative to the broader market, dermatology represented about 2% of total M&A value ($6.4B of $358.8B) and cash-only value ($5.2B of $312.3B), underscoring limited capital concentration compared to Cancer, Neurologic, and Cardiovascular.
Key deals included Johnson & Johnson’s $1.3B upfront acquisition of Yellow Jersey Therapeutics in May 2024, closed July 11, 2024, for atopic dermatitis; Organon’s acquisition of Dermavant in September 2024 for up to $1.2B, including $175M upfront plus $75M regulatory and $950M commercial milestones, closed October 28, 2024, in psoriasis and atopic dermatitis; Crown Laboratories’ acquisition of Revance Therapeutics, initially priced at $6.66 per share with an 89% one-day premium and $924M enterprise value, later amended to $3.1-$3.65 per share, closed February 6, 2025, in aesthetics; Solventum’s acquisition of Acera Surgical in November 2025 for $725M upfront plus up to $125M contingent, closed December 23, 2025, in wound care devices; and Johnson & Johnson’s $850M upfront acquisition of Proteologix in May 2024, closed June 20, 2024, for preclinical atopic dermatitis and asthma programs.
Dermatology M&A activity moderated in 2025, with 14 deals totaling $900M in aggregate value, including contingent payments, reflecting a significantly smaller market by value. In contrast, 2024 recorded 19 transactions and $5.4B in total deal value, accounting for most of the two-year aggregate. From 2024 to 2025, the sector completed 33 deals valued at $6.4B.
In 2025, dermatology M&A totaled 14 deals and $800M in cash-only consideration, excluding contingent payments, indicating a relatively modest level of committed capital compared with the prior year. In contrast, 2024 recorded 19 transactions and $4.4B in cash value, accounting for most capital deployed over the two years. From 2024 to 2025, the sector completed 33 deals representing $5.2B in cash-only value.
In 2025, the average upfront cash and equity consideration per dermatology M&A transaction was $258M, reflecting smaller deal sizes on an upfront basis. In comparison, 2024 averaged $551M per deal, with upfront values more than double 2025 levels. Overall data indicate a material decline in average upfront pricing in 2025 relative to 2024.
In 2025, the median upfront cash and equity consideration in dermatology M&A was $36M, reflecting a significantly lower typical deal size. By comparison, the 2024 median reached $513M, underscoring materially larger upfront commitments.
Top Therapy Areas – M&A in 2024-2025
From 2024 to 2025, total M&A value, including contingent payments, reached $358.8B across all listed therapy areas, with capital heavily concentrated in a small number of categories. Cancer led by a wide margin at $109.3B, representing about 30% of total deal value. Neurologic and Cardiovascular followed at $37.1B and $36.8B, respectively, each accounting for about 10%. Combined, these three areas generated $183.2B, or roughly 51% of the $358.8B total, indicating that more than half of industry M&A value was concentrated in just three segments. By comparison, Dermatologic M&A totaled $6.4B, or around 2% of the overall market. Cancer deal value was 17 times larger than Dermatologic, while Neurologic and Cardiovascular were each about 6 times larger over the same period.
From 2024 to 2025, the dataset recorded 640 total M&A transactions across the listed therapy areas, with deal activity concentrated in a limited number of segments. Cancer led with 161 deals, representing about 25% of total volume. Neurologic followed with 141 deals, or about 22%, while Cardiovascular ranked third with 61 deals, or about 10%. Combined, these three therapy areas accounted for 363 transactions, or roughly 57% of the total deal count, underscoring the concentration of market activity. Dermatologic recorded 33 deals, or about 5% of total volume. This placed it well below the top three categories, at approximately one-fifth of Cancer’s deal count, about one-quarter of Neurologic’s, and slightly over half of Cardiovascular’s transaction volume.
From 2024 to 2025, total cash M&A value, excluding contingent payments, reached $312.3B across the listed therapy areas, with capital concentrated in a small number of segments. Cancer led by a wide margin at $100B, representing about 32% of total cash value. Neurologic followed at $34B, or about 11%, and Cardiovascular at $30.2B, or about 10%. Combined, these three areas accounted for $164.2B, roughly 53% of total committed cash consideration, indicating that more than half of deployed capital was concentrated in these categories. Dermatologic cash-only M&A totaled $5.2B, or around 2% of the overall market. On a cash basis, Cancer was 19 times larger than Dermatologic, while Neurologic and Cardiovascular were each about 6 to 7 times larger over the same period.
From 2024 to 2025, average upfront cash and equity consideration varied significantly by therapy area, with several segments posting materially larger deal sizes than Dermatologic. Pulmonary led at $3.3B, followed by Genitourinary at $2.3B and Hepatic at $2.3B. High volume areas such as Cancer and Cardiovascular also recorded strong averages at $1.3B and $1.3B, respectively. Infectious averaged $1.9B, while Neurologic stood at $872M. By comparison, Dermatologic averaged $471M in upfront consideration. About 3 times smaller than Cancer and roughly 7 times smaller than Pulmonary, placing Dermatologic among the lower average upfront values across the listed therapy areas.
Across 2024 to 2025, median upfront cash and equity, reflecting the typical deal size, varied widely by therapy area, ranging from modest to exceptionally large transactions. Hepatic recorded the highest median at $2.4B, followed by Inflammation at $919M, Renal at $800M, and Dental at $788M, indicating substantially larger typical upfront commitments in these categories. Among higher activity segments, Cardiovascular posted a median of $479M, while Cancer stood at $353M and Neurologic at $151M, highlighting smaller typical upfront values in Neurologic relative to Cancer and Cardiovascular. Dermatologic recorded a median upfront of $275M. This placed it above Neurologic at $151M, Infectious at $244M, and Pulmonary at $26M, but below Cancer at $353M and Cardiovascular at $479M, positioning Dermatologic in the mid-range of typical upfront deal sizes.
Notable Dermatology M&A – 2024-2025
Johnson & Johnson acquired Yellow Jersey Therapeutics from Numab – May 2024
Johnson & Johnson, through Cilag, acquired Yellow Jersey Therapeutics, a subsidiary formed by Numab to hold its Phase I antibody asset NM-26 for Dermatologic / Dermatitis. The transaction followed Numab’s demerger of NM-26 into Yellow Jersey as a standalone entity. Johnson & Johnson secured global rights to develop, manufacture, and commercialize NM-26 for atopic dermatitis and follow-on indications, with Numab shareholders receiving $1.3B upfront. The acquisition was completed on July 11, 2024.
Organon acquired Dermavant – September 2024
Organon agreed to acquire Dermavant, including Vtama cream, a non-steroidal topical therapy approved for plaque psoriasis and under FDA review for atopic dermatitis. Dermavant holds global rights excluding China and has out-licensed Japan rights. The transaction provides Dermavant shareholders with up to $1.2B in total consideration, including $175M upfront, up to $75M in regulatory milestones tied to atopic dermatitis approval, and up to $950M in commercial milestones, plus tiered royalties on net sales. Organon will also assume up to $286M in liabilities. The acquisition, signed at the approved stage, was completed on Oct 28, 2024.
Crown Laboratories acquired Revance Therapeutics to take the company private – August 2024
Crown Laboratories agreed to acquire Revance Therapeutics in an approved stage transaction to take the company private. Revance’s portfolio includes aesthetics and dermatology assets such as Daxxify for cervical dystonia, the RHA collection, SkinPen, PanOxyl, Blue Lizard, StriVectin for aging, and preclinical topical neuromodulators. The initial offer was $6.66 per share in cash, representing an 89% one day premium and a total enterprise value of $924M. On December 9, 2024, the price was amended to $3.1 per share, and on January 21, 2025, revised to $3.65 per share with the tender offer extended to February 4, 2025. The transaction closed on Feb. 6, 2025.
Solventum acquired Acera Surgical – November 2025
Solventum acquired Acera Surgical, a developer of fully engineered synthetic tissue matrices for wound care, including FDA-approved Restrata sheet, Restrata meshed, Restrata minimatrix, and Cerafix. The transaction strengthens Solventum’s MedSurg portfolio and expands its presence in the synthetic tissue matrices market, with plans to leverage its global commercial platform to drive adoption. Acera shareholders received $725M in cash up front and are eligible for up to $125M in contingent payments tied to future milestones. The acquisition was completed on Dec 23, 2025.
Johnson & Johnson acquired Proteologix – May 2025
Johnson & Johnson acquired Proteologix, a preclinical-stage company developing bispecific antibodies, including PX128 targeting IL-13 plus TSLP for atopic dermatitis and PX130 targeting IL-13 plus IL-22 for asthma, as well as additional early-stage programs. The transaction strengthens Johnson & Johnson’s dermatology and inflammation pipeline at the Preclinical / IND stage. Proteologix received $850M upfront in cash and is eligible for an undisclosed milestone payment. The acquisition was completed on June 20, 2024.
Also check out Global Healthcare and Life Sciences IPO Activity – 2025 Review
